Tel: 604-675-8000 ext. 7024
· Pancreatic Cancer, Cancer-assoicated Fibroblast
Pancreatic cancer has the worst prognosis in oncology, owing to early metastasis and severe resistance to chemotherapy and chemoradiotherapy. Recent evidence has implicated the influence of the tumor microenvironment on the response to pulsatile maximum tolerated dose and low-dose metronomic chemotherapy regimens. My research focuses on examining the molecular interactions between pancreatic cancer cells and cancer-associated fibroblasts (CAFs), in the tumor microenvironment, to determine how CAFs mediate chemotherapy. Through our research we hope to identify novel therapeutic targets and to develop more effective treatment strategies to improve the overall prognosis this destructive disease.